Pulmonary arterial hypertension: trials for referral
349 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
349 trials shown
Phase 312 sites
RecruitingCzechia, Germany, Spain, France, Georgia, Japan
NCT07234032
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Insmed Incorporated
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT07781709
Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass-Substudy
University of Pennsylvania
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govNo phase19 sites
RecruitingChina, United States
NCT07214376
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
Pulnovo Medical, Inc.
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 2/315 sites
Not yet recruitingUnited States
NCT07923526
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
United Therapeutics
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 216 sites
Not yet recruitingUnited States
NCT07923591
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
United Therapeutics
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 41 site
RecruitingCanada
NCT07140484
Sotatercept in Pulmonary Arterial Hypertension
University of Alberta
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govNo phase70 sites
RecruitingAustria, Czechia, Germany, Denmark, Italy, Netherlands
NCT06526195
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Abbott Medical Devices
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 2/31 site
RecruitingSwitzerland
NCT07824674
The Effect of Additive On-Demand Sildenafil vs. Dextrose Candy on Maximum Exercise Capacity in Pulmonary Arterial Hypertension
Silvia Ulrich
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingRussia
NCT07914933
The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary Thromboendarterectomy
Meshalkin Research Institute of Pathology of Circulation
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 43 sites
RecruitingIndia
NCT07600723
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
Merck Sharp & Dohme LLC
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT01712620
Spironolactone for Pulmonary Arterial Hypertension
National Institutes of Health Clinical Center (CC)
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 347 sites
RecruitingBelgium, Bulgaria, Belarus, China, Spain, France
NCT05179876
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
Actelion
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govNo phase41 sites
RecruitingUnited States
NCT06911632
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Tempus AI
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govNo phase4 sites
RecruitingCzechia
NCT07161908
Controlled Remote Monitoring and Optimization of Oxygen Therapy in Preterm Infants
Institute of Health Information and Statistics of the Czech Republic
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 235 sites
RecruitingAustralia, Colombia, Germany, Spain, France, United Kingdom
NCT05587712
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Merck Sharp & Dohme LLC
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/27 sites
RecruitingSpain, United Kingdom, United States
NCT07143448
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
35Pharma Inc., a GSK company
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07907757
Colchicine in Pulmonary Artery Hypertension Patients
Ain Shams University
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 1/23 sites
RecruitingUnited States
NCT07123779
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
35Pharma Inc., a GSK company
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govNo phase3 sites
RecruitingChina
NCT07667829
Vasopressor Agents in Pulmonary Hypertension Crisis
China National Center for Cardiovascular Diseases
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 37 sites
RecruitingAustria, Germany, Spain, France, Hungary, Slovakia
NCT06350032
Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
AOP Orphan Pharmaceuticals AG
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 419 sites
RecruitingUnited States
NCT05213676
De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia
The University of Texas Health Science Center, Houston
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 437 sites
RecruitingArgentina, Austria, Czechia, Germany, Spain, France
NCT06317805
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
AOP Orphan Pharmaceuticals AG
Pre-treatment window Registry sentence: “Newly diagnosed treatment-naïve PAH patients (PH group I) defined as receiving no specific therapy to treat PAH”
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 40 sites
Not yet recruiting
NCT07899905
A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension (MK-7962-022)
Merck Sharp & Dohme LLC
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 228 sites
RecruitingBelgium, Germany, Spain, France, Greece, Italy
NCT07441200
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
NS Pharma, Inc.
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 22 sites
RecruitingJapan, United States
NCT07441278
A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NS Pharma, Inc.
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 216 sites
RecruitingSpain, South Korea, Poland, Romania, Serbia, United States
NCT07473700
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
Tectonic Operating Company, Inc.
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 245 sites
RecruitingAustralia, Belgium, Czechia, Germany, Spain, France
NCT07318597
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
Regeneron Pharmaceuticals
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT07895966
Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis
University of Utah
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 3186 sites
RecruitingArgentina, Austria, Australia, Belgium, Brazil, Switzerland
NCT07179380
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Insmed Incorporated
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07839585
A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)
Merck Sharp & Dohme LLC
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States108 open trials
- China44 open trials
- France35 open trials
- Germany30 open trials
- Spain28 open trials
- United Kingdom27 open trials
- Switzerland26 open trials
- Poland20 open trials
- Italy18 open trials
- Czechia15 open trials
- Canada15 open trials
- Belgium15 open trials
- Brazil15 open trials
- Austria14 open trials
- South Korea13 open trials
- Australia11 open trials
- Egypt11 open trials
- Netherlands10 open trials
- Romania10 open trials
- Argentina9 open trials
- Japan8 open trials
- Türkiye8 open trials
- Taiwan7 open trials
- Hungary7 open trials
- Portugal7 open trials
- Greece7 open trials
- Latvia7 open trials
- Denmark6 open trials
- Israel6 open trials
- Mexico5 open trials
- Serbia4 open trials
- New Zealand4 open trials
- Lithuania4 open trials
- Russia3 open trials
- Colombia3 open trials
- Singapore3 open trials
- Hong Kong3 open trials
- Georgia2 open trials
- Saudi Arabia2 open trials
- Ukraine2 open trials
- South Africa2 open trials
- Bulgaria2 open trials
- Slovakia2 open trials
- Malaysia2 open trials
- Sweden2 open trials
- Chile2 open trials
- Norway2 open trials
- India1 open trial
- Vietnam1 open trial
- Belarus1 open trial
- Thailand1 open trial
- Uruguay1 open trial
- Bosnia and Herzegovina1 open trial
- Ireland1 open trial
- Puerto Rico1 open trial
- Finland1 open trial
- Bolivia1 open trial
- Syria1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Amsterdam UMC Location Vrije Universiteit Amsterdam
Amsterdam, Netherlands
1 trial · 11 publications · ROR
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
Turin, Italy
1 trial · 10 publications · ROR
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Brescia, Italy
3 trials · 17 publications · ROR
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
7 trials · 16 publications · ROR
First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
5 trials · 14 publications · ROR
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
3 trials · 10 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Opened for recruitment
Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass-Substudy
NCT07781709 · No phase · United States
Source: ClinicalTrials.govNew in the registry
A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-038)
2025-521970-33-00 · Phase 3 · Belgium, Czechia, Germany, Denmark, Spain, France
Source: EU CTISStopped early
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
NCT04816604 · Phase 2 · Australia, Czechia, Germany, Spain, France, United Kingdom
Source: ClinicalTrials.govOpened for recruitment
NCT07481981 · Phase 3 · Argentina, Austria, Australia, Belgium, Germany, Spain
Source: ClinicalTrials.govPhase changed: Phase 2/3 → Phase 3
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332 · Phase 3 · Argentina, Austria, Australia, Belgium, Canada, Czechia
Source: ClinicalTrials.govOpened for recruitment
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07441200 · Phase 2 · Belgium, Germany, Spain, France, Greece, Italy
Source: ClinicalTrials.govOpened for recruitment
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada
Source: ClinicalTrials.govPhase changed: Phase 1 → Phase 1/2
NCT06137742 · Phase 1/2 · Australia, Belgium, China, Czechia, Germany, Spain
Source: ClinicalTrials.govClosed for recruitment
NCT05649748 · Phase 2/3 · Argentina, Austria, Belgium, Brazil, Germany, Denmark
Source: ClinicalTrials.govOpened for recruitment
NCT03683186 · Phase 3 · Argentina, Austria, Australia, Belgium, Bulgaria, Brazil
Source: ClinicalTrials.govClosed for recruitment
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada
Source: ClinicalTrials.govClosed for recruitment
NCT03683186 · Phase 3 · Argentina, Austria, Australia, Belgium, Bulgaria, Brazil
Source: ClinicalTrials.govOpened for recruitment
NCT05649748 · Phase 2/3 · Argentina, Austria, Belgium, Brazil, Germany, Denmark
Source: ClinicalTrials.govNew in the registry
A Long-term Follow-up Study of Sotatercept for PAH Treatment
NCT04796337 · Phase 3 · Austria, Belgium, Czechia, Germany, Denmark, Spain
Source: EU CTISOpened for recruitment
2025-523010-89-00 · Phase 1/2 · Czechia, Germany, Spain, Hungary, Poland
Source: EU CTISStatus changed: Recruiting → Not yet recruiting
NCT07481981 · Phase 3 · Argentina, Austria, Australia, Belgium, Germany, Spain
Source: ClinicalTrials.gov
Show more
Status changed: Recruiting → Not yet recruiting
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07441200 · Phase 2 · Belgium, Germany, Spain, France, Greece, Italy
Source: ClinicalTrials.govNew in the registry
Home-based Inspiratory Muscle Training in Pulmonary Hypertension
NCT07917416 · No phase · Spain
Source: ClinicalTrials.govNew in the registry
Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary Conditions
NCT07915882 · No phase · United States
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 2Ended 30 Sept 2026
Completed60 participants
NCT07918976
Effects of Inhaled Nitric Oxide on Sublingual Microcirculation in Patients With Right Ventricular Dysfunction After Cardiac Surgery
Phase 2/3Ended 23 Sept 2026
Completed100 participants
NCT07462260
Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)
Phase 2Ended 9 Sept 2026
Stopped early74 participants
NCT04816604
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Reason given: Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect study interpretation or the overall benefit-risk.
Phase 2Ended 28 Aug 2026
Completed10 participants
2025-521155-23-00
An Open-Label Extension Study for Participants with PAH Who Have Previously Participated in a Clinical Trial with PF-07868489
Phase 1/2Ended 31 Jul 2026
Completed97 participants
NCT06137742
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
No phaseEnded 17 Jul 2026
Phase 3Ended 10 Jul 2026
No phaseEnded 10 Jul 2026
Early Phase 1Ended 6 Jun 2026
Completed3 participants
NCT06653556
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
No phaseEnded 1 Jun 2026
Completed72 participants
NCT07478094
Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost
Phase 3Ended 1 May 2026
Stopped early7 participants
NCT05140525
Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH
Reason given: Sponsor Requested
No phaseEnded 29 Apr 2026
Completed314 participants
NCT05776225
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
- Screening for Pulmonary Hypertension in Interstitial Lung Disease: Preliminary Results from the PHINDER Study. · Advances in therapy, 2026
No phaseEnded 20 Apr 2026
Completed40 participants
NCT07206173
Londrina Activities of Daily Living Protocol in Pulmonary Hypertension
Phase 2Ended 16 Apr 2026
Withdrawn before start0 participants
NCT07221513
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
Reason given: Sponsor decision
Phase 2Ended 14 Apr 2026
Completed20 participants
NCT05679570
Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)
Phase 2Ended 9 Apr 2026
Completed165 participants
NCT04945460
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
No phaseEnded 9 Apr 2026
Completed7 participants
NCT06907693
The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI
Phase 2/3Ended 1 Apr 2026
No phaseEnded 31 Mar 2026
Completed19 participants
NCT06543745
Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension
No phaseEnded 1 Mar 2026
Completed50 participants
NCT06671171
Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial
Show more
Phase 2Ended 27 Feb 2026
No phaseEnded 20 Jan 2026
Withdrawn before start0 participants
NCT04947384
Pulmonary Vascular Hemodynamics Before and After Mitral Valve Procedures
Reason given: PI moved to a different institution. Low enrollment rate.
No phaseEnded 15 Jan 2026
Completed144 participants
NCT04373902
Physiological-based Cord Clamping in Congenital Diaphragmatic Hernia
No phaseEnded 15 Jan 2026
Phase 4Ended 14 Jan 2026
Completed30 participants
NCT06409026
Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
- Sotatercept in Pulmonary Arterial Hypertension: Central, Hematologic, and Peripheral Mechanisms of Benefit. · Journal of the American College of Cardiology, 2026
- Sotatercept Improves Right Heart Mechanics Despite Reduced Myocardial Contractility in Pulmonary Arterial Hypertension: A Prospective Exercise Hemodynamic Study. · Circulation, 2026
Phase 2Ended 13 Jan 2026
Completed52 participants
NCT05179356
Dapagliflozin in Pulmonary Arterial Hypertension
- Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: The DAPAH randomized controlled trial. · The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2026
No phaseEnded 1 Jan 2026
Completed112 participants
NCT05624242
Assessment of Right Ventricular Function by Cardiac MRI in Patients With Pulmonary Arterial Hypertension (IRMA)
- Cardiac MRI differentiates classical idiopathic pulmonary arterial hypertension from lung phenotype and group 3 pulmonary hypertension. · Respiratory medicine and research, 2026
No phaseEnded 31 Dec 2025
Phase 3Ended 31 Dec 2025
Completed687 participants
NCT03626688
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Phase 2Ended 31 Dec 2025
Withdrawn before start0 participants
NCT06122922
Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN)
Reason given: Funding withdrawn
Phase 3Ended 31 Dec 2025
Completed28 participants
NCT04039464
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
Phase 2Ended 31 Dec 2025
Completed5 participants
NCT03814317
Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension
No phaseEnded 31 Dec 2025
No phaseEnded Dec 2025
Withdrawn before start0 participants
NCT04254289
Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension
Reason given: Lack of enrollment
No phaseEnded 30 Dec 2025
Completed400 participants
NCT03729544
Computerized Decision Support to Increase Detection of Chronic Thromboembolic Pulmonary Hypertension in Patients With Prior Pulmonary Embolism
Phase 3Ended 22 Dec 2025
Completed390 participants
NCT05934526
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
No phaseEnded 1 Dec 2025
Withdrawn before start0 participants
NCT06145880
ADOPT: Improving Diagnosis of Pulmonary Hypertension With AI and Echo
Reason given: The Commercial Funder withdrew the funding
Phase 3Ended 27 Nov 2025
Completed165 participants
NCT02932410
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
- Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial. · The Journal of pediatrics, 2026
No phaseEnded 21 Nov 2025
Phase 2Ended 20 Nov 2025
Completed164 participants
NCT06664801
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
Phase 3Ended 6 Nov 2025
Completed46 participants
NCT05818137
A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)
No phaseEnded 25 Oct 2025
Completed66 participants
NCT06350773
Phosphodiesterase Type 5 Inhibitors in Patients With Group 2 Pulmonary Hypertension
Phase 4Ended 15 Sept 2025
Completed18 participants
NCT02759419
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
No phaseEnded 31 Aug 2025
Completed30 participants
NCT07844213
Early Postoperative Triple Targeted Therapy in Patients With CHD-PAH in the "Grey Zone"
Phase 2Ended 25 Aug 2025
Completed260 participants
NCT05737940
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
Phase 2Ended 19 Aug 2025
Completed73 participants
NCT03617458
Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension
Phase 4Ended 13 Aug 2025
Phase 1/2Ended 11 Aug 2025
No phaseEnded 1 Aug 2025
Completed52 participants
NCT07416331
Impact Of Using LevosemidanVersus DobutamineOn Right Ventricular Function In AdultPatients Undergoing Elective Valve Replacement Surgery
No phaseEnded 1 Aug 2025
Completed100 participants
NCT06778330
The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension
Phase 2Ended 31 Jul 2025
Stopped early35 participants
NCT05339087
Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
Reason given: Strategic re-prioritization by the IMP supplier. Decision not safety-related.
No phaseEnded 31 Jul 2025
Completed10 participants
NCT05339386
Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension
Phase 1Ended 29 Jul 2025
Stopped early4 participants
NCT06581159
Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
Reason given: Sponsor's Decision
Phase 2Ended 23 Jul 2025
Stopped early202 participants
NCT01065454
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
Reason given: The sponsor terminated the study for strategic reasons. This decision was not due to safety concerns for participants receiving treatment at the time the study was terminated.
Phase 2/3Ended 3 Jul 2025
Phase 2Ended 3 Jul 2025
No phaseEnded 1 Jul 2025
Completed40 participants
NCT06384534
Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD)
No phaseEnded 13 Jun 2025
Completed150 participants
NCT05568927
Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism
No phaseEnded May 2025
Withdrawn before start0 participants
NCT05332873
Rivet PVS Therapy in Group 2 PH-HFpEF Canada
Reason given: Commercial decision
Phase 2Ended 19 May 2025
Not medical advice. fetched 11 Nov 2026